Potential utility of plasma fatty acid analysis the diagnosis of cystic fibrosis

被引:21
作者
Batal, Ibrahim
Ericsoussi, Mhd-Bassel
Cluette-Brown, Joanne E.
O'Sullivan, Brian P.
Freedman, Steven D.
Savaille, Juanito E.
Laposata, Michael
机构
[1] Massachusetts Gen Hosp, Dept Pathol, Div Lab Med, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Univ Massachusetts, Dept Pediat, Mem Hlth Care, Worcester, MA 01605 USA
[4] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA
[5] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
关键词
D O I
10.1373/clinchem.2006.077008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: An altered distribution of fatty acids in cells and tissues is found in patients with cystic fibrosis (CF). In this study, we assessed the potential role of plasma fatty acid analysis in the diagnosis of CF. Methods: In this 2-part study, we first used gas chrornatography-mass spectrometry to analyze fatty acids in plasma from 13 CF patients and 11 controls without CF. We then used the fatty acid distribution data to identify the fatty acids or multiple fatty acid calculations most effective in identifying CF patients. Part 2 of the study was a blinded analysis of 10 CF patients and 9 controls to directly test the effectiveness of the diagnostic parameters for CF identified from the plasma fatty acid analysis. Results: In the nonblinded trial, the multiplication product of (18:2 n-6) X (22:6 n-3) (each as percentage of total plasma fatty acid) was the most effective indicator for distinguishing patients with CF from controls (P=0.0003). In part 2 (the blinded trial), this multiplication product was also the most effective indicator for distinguishing CF patients from controls (P=0.0008). Conclusions: The product of (18:2 n-6) X (22:6 n-3) is effective for distinguishing CF patients from persons without CF. This diagnostic marker may have value as an alternative to the sweat chloride test in selected patients being evaluated for CF. (c) 2007 American Association for Clinical Chemistry
引用
收藏
页码:78 / 84
页数:7
相关论文
共 28 条
[1]  
ALTON EWFW, 1990, EUR RESPIR J, V3, P922
[2]   Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts [J].
Benabdeslam, H ;
Garcia, I ;
Bellon, G ;
Gilly, R ;
Revol, AE .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 67 (05) :912-918
[3]   Monitoring growth, body composition, pubertal and bone status [J].
Borowitz, D ;
Baker, RD ;
Stallings, V .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 35 (03) :246-259
[4]   PATHOLOGICAL REGULATION OF ARACHIDONIC-ACID RELEASE IN CYSTIC-FIBROSIS - THE PUTATIVE BASIC DEFECT [J].
CARLSTEDTDUKE, J ;
BRONNEGARD, M ;
STRANDVIK, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (23) :9202-9206
[5]  
Cystic Fibrosis Foundation, SWEAT TEST
[6]   Gas chromatographic quantification of fatty acid methyl esters: flame ionization detection vs. electron impact mass spectrometry [J].
Dodds, ED ;
McCoy, MR ;
Rea, LD ;
Kennish, JM .
LIPIDS, 2005, 40 (04) :419-428
[7]  
Farrell PM, 1996, PEDIATRICS, V97, P524
[8]   FATTY-ACID ABNORMALITIES IN CYSTIC-FIBROSIS [J].
FARRELL, PM ;
MISCHLER, EH ;
ENGLE, MJ ;
BROWN, DJ ;
LAU, SM .
PEDIATRIC RESEARCH, 1985, 19 (01) :104-109
[9]   DELAYED DIAGNOSIS OF CYSTIC-FIBROSIS IN CHILDREN WITH A RARE GENOTYPE (DELTA-F508/R117H) [J].
FITZGERALD, D ;
VANASPEREN, P ;
HENRY, R ;
WATERS, D ;
FREELANDER, M ;
WILSON, M ;
WILCKEN, B ;
GASKIN, K .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1995, 31 (03) :168-171
[10]   A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice [J].
Freedman, SD ;
Katz, MH ;
Parker, EM ;
Laposata, M ;
Urman, MY ;
Alvarez, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :13995-14000